Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma
Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that rarely metastasizes but lacks effective systemic therapy once it propagates. In some reports, high interleukin-6 (IL-6) production promotes tumor growth by autocrine stimulation and tocilizumab, an IL-6 receptor antagonist, can...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2021/5532258 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561465359335424 |
|---|---|
| author | Hideaki Sabe Akitomo Inoue Shigenori Nagata Yoshinori Imura Toru Wakamatsu Satoshi Takenaka Hironari Tamiya |
| author_facet | Hideaki Sabe Akitomo Inoue Shigenori Nagata Yoshinori Imura Toru Wakamatsu Satoshi Takenaka Hironari Tamiya |
| author_sort | Hideaki Sabe |
| collection | DOAJ |
| description | Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that rarely metastasizes but lacks effective systemic therapy once it propagates. In some reports, high interleukin-6 (IL-6) production promotes tumor growth by autocrine stimulation and tocilizumab, an IL-6 receptor antagonist, can control AFH growth. Here, we present a case report on a patient with local recurrence and distant lymph node metastasis of AFH treated with tocilizumab. As a result, the inhibition of the IL-6 signaling pathway controlled paraneoplastic inflammatory syndrome (PIS); however, the local recurrent tumor progressed. This case implied that IL-6 is not necessarily the cause of tumor growth in AFH. Therefore, physicians should bear in mind that watchful observation is needed whether tocilizumab can control tumor progression despite the amelioration of PIS associated with the attenuated effect of IL-6 on AFH. |
| format | Article |
| id | doaj-art-e9b7599240d74de9b90a8fd27856c480 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-e9b7599240d74de9b90a8fd27856c4802025-02-03T01:24:59ZengWileyCase Reports in Oncological Medicine2090-67062090-67142021-01-01202110.1155/2021/55322585532258Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous HistiocytomaHideaki Sabe0Akitomo Inoue1Shigenori Nagata2Yoshinori Imura3Toru Wakamatsu4Satoshi Takenaka5Hironari Tamiya6Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanAngiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that rarely metastasizes but lacks effective systemic therapy once it propagates. In some reports, high interleukin-6 (IL-6) production promotes tumor growth by autocrine stimulation and tocilizumab, an IL-6 receptor antagonist, can control AFH growth. Here, we present a case report on a patient with local recurrence and distant lymph node metastasis of AFH treated with tocilizumab. As a result, the inhibition of the IL-6 signaling pathway controlled paraneoplastic inflammatory syndrome (PIS); however, the local recurrent tumor progressed. This case implied that IL-6 is not necessarily the cause of tumor growth in AFH. Therefore, physicians should bear in mind that watchful observation is needed whether tocilizumab can control tumor progression despite the amelioration of PIS associated with the attenuated effect of IL-6 on AFH.http://dx.doi.org/10.1155/2021/5532258 |
| spellingShingle | Hideaki Sabe Akitomo Inoue Shigenori Nagata Yoshinori Imura Toru Wakamatsu Satoshi Takenaka Hironari Tamiya Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma Case Reports in Oncological Medicine |
| title | Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma |
| title_full | Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma |
| title_fullStr | Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma |
| title_full_unstemmed | Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma |
| title_short | Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma |
| title_sort | tocilizumab controls paraneoplastic inflammatory syndrome but does not suppress tumor growth of angiomatoid fibrous histiocytoma |
| url | http://dx.doi.org/10.1155/2021/5532258 |
| work_keys_str_mv | AT hideakisabe tocilizumabcontrolsparaneoplasticinflammatorysyndromebutdoesnotsuppresstumorgrowthofangiomatoidfibroushistiocytoma AT akitomoinoue tocilizumabcontrolsparaneoplasticinflammatorysyndromebutdoesnotsuppresstumorgrowthofangiomatoidfibroushistiocytoma AT shigenorinagata tocilizumabcontrolsparaneoplasticinflammatorysyndromebutdoesnotsuppresstumorgrowthofangiomatoidfibroushistiocytoma AT yoshinoriimura tocilizumabcontrolsparaneoplasticinflammatorysyndromebutdoesnotsuppresstumorgrowthofangiomatoidfibroushistiocytoma AT toruwakamatsu tocilizumabcontrolsparaneoplasticinflammatorysyndromebutdoesnotsuppresstumorgrowthofangiomatoidfibroushistiocytoma AT satoshitakenaka tocilizumabcontrolsparaneoplasticinflammatorysyndromebutdoesnotsuppresstumorgrowthofangiomatoidfibroushistiocytoma AT hironaritamiya tocilizumabcontrolsparaneoplasticinflammatorysyndromebutdoesnotsuppresstumorgrowthofangiomatoidfibroushistiocytoma |